This webinar has ended
You can no longer register for this event.
The recording will be uploaded very shortly and will be available on-demand.
Defining the Future of R&D Acceleration Through Data & AI: A discussion of case studies that highlight the future of computational technologies for biopharma
About the Webinar
Life sciences R&D is at an inflexion point. Data-rich simulation, accelerated computing, and practical AI are reshaping how we design studies, make go/no-go calls, and de-risk development, without compromising patient safety. Early proof points are here; but the real acceleration is just beginning.
In this QuantHealth webinar, we’ll dive into case studies that show what’s working now and what’s next. Your host will be Gabriel Eichler, Founder & Managing Director, Oak Health Partners (former-Novartis, data42), with guests David Berry, Co-Founder & Managing Partner, Averin (former-Valo Health), and Sid Jain, SVP, Clinical Development, Recursion, joining for a candid, case-driven conversation.
We’ll unpack what delivers measurable value today, the pitfalls slowing adoption, and practical playbooks for scaling AI across R&D.
You’ll leave with: concrete examples, metrics that matter, and a forward view of the operating principles that will define AI-driven life sciences.
Register to learn how teams in leading Life Science companies utilize AI and Data to accelerate their R&D pipelines.
Agenda
● What leading AI-driven R&D organizations are doing now - case studies of speed and value-creation.
● Challenges we’ll need to overcome to see sustained and broad adoption.
● Predictions for what we’ll see as AI-driven operating principles of the future.
Meet the Speakers
Dr. Gabriel Eichler is the Founder and Managing Director of the boutique consulting firm – Oak Health Partners AG. Prior to this Dr. Eichler was the VP and Chief Data Officer for Novartis’s enterprise-wide R&D & Real-World data & analytics project, Data42. He and his team of 60+ staff members (and leadership peers) built the R&D and RWD data and analytics infrastructure for Novartis. Prior to working at Novartis, Dr. Eichler has spent the 15 years working to apply healthcare technologies to problems in the pharmaceutical/biotech industry and the delivery of healthcare. He also has served as Data & Analytics lead at the Harvard Business School’s Kraft Precision Medicine Accelerator, VP of Products at GNS Healthcare and General Manager at PatientsLikeMe and he spent time at McKinsey & Co. Dr. Eichler completed his MSc. and PhD in Bioinformatics at Boston University and the National Cancer Institute’s Laboratory of Molecular Pharmacology, jointly. His BSE is in Computer Science from the University of Pennsylvania. He has authored over 40 scholarly manuscripts and book chapters. He is an investor and advisor to numerous early-stage startup companies. Dr. Eichler is also a seasoned public speaker and has delivered over 100 lectures globally on clinical data platforms, artificial intelligence, personalized medicine, genomics, patient centricity, complex data systems, open innovation, and biomedical informatics.
David is Co-Founder and Managing Partner at Averin. As an innovator and a company builder, he has been driven by the power of technology to transform industries. David has been a founder of over 30 companies, including 7 that have been valued at over $1B. David was previously a General Partner at Flagship Pioneering. He was also founder and CEO of Valo Health, where he raised over $500M and executed a transformative partnership with Novo Nordisk. David received his M.D. from Harvard Medical School and his Ph.D. from MIT through the biological engineering division, where he worked with Professors Robert Langer and Ram Sasisekharan. David works closely with Biolinq amongst other Averin companies.
Sid Jain is a healthcare innovator passionate about reimagining clinical development through the power of data, technology, and biology. As SVP of Clinical Development & Data Science at Recursion, Sid leads teams that blend AI, real-world data, computational biology, and clinical expertise to modernize how therapies are developed. His focus is on transforming clinical development into a more predictive, efficient, and patient-centric process—seamlessly bridging the gap between drug discovery and development in Recursion’s TechBio platform. Prior to Recursion, Sid served as Vice President of Global Development Data Science & Digital Health at Johnson & Johnson, where he led groundbreaking initiatives like real-world registries and AI-powered trial platforms that accelerated development timelines. Over his 20-year career, he has built and scaled data science and digital health teams across biopharma and health tech companies, including ConcertAI and NantHealth. Sid is also a committed advocate for advancing diversity, equity, and inclusion in clinical research.